Skip to main content

Table 1 Outcome according to clinical characteristics in the 100 PDAC patients enrolled in the present study

From: Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

Characteristics

N (=%)

OS months

(95% CI)

P

No. patients

All

100

14.0 (12.1–15.8)

 

Age, years

≤65

43

15.2 (13.3–16.8)

0.361

 

>65

57

14.1 (11.1–17.0)

 

Sex

Male

47

13.0 (11.1–14.9)

0.814

 

Female

53

15.0 (11.9–18.1)

 

Resection status

R0

56

15.2 (12.3–21.6)

0.474

 

R1

44

13.5 (11.2–31.0)

 

Lymph node

No

10

18.5 (7.6–32.4)

0.521

 

Yes

90

14.2 (12.2–15.9)

 

Grading

1–2

36

15.5 (11.5–18.1)

0.097

 

3

64

12.1 (8.4–15.8)

Â